B-Cell Growth Factor

Total Page:16

File Type:pdf, Size:1020Kb

B-Cell Growth Factor Proc. Natl Acad. Sci. USA Vol. 79, pp. 7455-7459, December 1982 Immunology B-cell growth factor: Distinction from T-cell growth factor and B-cell maturation factor (B lymphocytes/T-cell hybridomas) TOMAS LEANDERSON*, ERIK LUNDGRENt, ERIK RUUTH*, HAKAN BORGt, HAKAN PERSSONt, AND ANTONIO COUTINHOt tLaboratory for Cell and Tissue Culture Research, *Institute of Pathology, and +Department of Immunology, UmeA University, S-901 87 UmeA, Sweden Communicated by Niels K. Jerne, July 12, 1982 ABSTRACT A T-cell hybridoma was derived by somatic cell We have initiated these studies by systematically screening hybridization between concanavalin A-activated BALB/c spleen hybridoma activities in different assays that measure either cells and the AKR thymoma BW 5147. Media conditioned by hy- growth or maturation ofall B lymphocytes, regardless ofclonal bridoma cells, even at high dilutions (1:1,000) support the growth specificity. We chose to study activated rather than resting B oflipopolysaccharide-stimulated B-cell blasts but not that ofT-cell cells because of the-overwhelming evidence that initiation of growth factor (TCGF)-reactive T-cells. This activity, herein des- cooperative B-cell responses requires direct cellular interaction ignated B-cell growth factor (BCGF), has a Mr of =20,000 and it (13, 14). In this report we describe a hybridoma clone secreting can readily be separated from TCGF (Mr "30,000) by gel filtra- a factor that supports growth but not maturation of lipopoly- tion. BCGF is constitutively produced by the hybridoma cells, it saccharide (LPS)-activated B-cell blasts and is devoid of is removed from conditioned media by incubation with target cells T-cell at +4°C, and it is equally effective on B-cell blasts carrying dif- growthfactor(TCGF) andT-cellreplacingfactor(TRF) activities. ferent major histocompatibility complex and Ig haplotypes. BCGF shows no T-cell replacing factor (TRF) activity, and it is poor in MATERIALS AND METHODS supporting the development of Ig-secreting plaque-forming cells Mice. BALB/c, C57BL/6, C3H/Hej, and C3H/Tif mice of in B-cell blast cultures. Terminal maturation, however, can be both sexes were bred in our colony and used at 8-12 weeks of induced in BCGF-dependent blasts by addition of conditioned age. media from normal helper T cell cultures, suggesting that two Cell Culture. BW 5147 cells and hybridoma cultures were distinct factors are involved in the helper cell-dependent growth kept in RPMI-1640 medium supplemented with 10% fetal calf and maturation of B lymphocytes. serum, antibiotics, 50 ,uM 2-mercaptoethanol, and 0.01 M Immune responses are the result ofextended clonal growth and Hepes; they were cultivated at 37°C in a humidified atmo- maturation ofspecific precursors preexisting in lowfrequencies. sphere. Much work has led to the isolation and characterization of Cell Fusion and Hybridoma Selection. Cell fusion was car- growth factors with specificities for cytotoxic T lymphocytes (1, ried out as described (15). Cells were cloned by seeding cells 2). Ever since 1970, various factors have been reported to in- at 1 or0.2 cell per culture inmicrotiter plates with afeeder layer teract directly with B lymphocytes (3, 4). Recently, evidence of peritoneal cells (limiting dilution). has been presented that activated B cells can grow under the Adsorptions. BCGF-containing supernatant was adsorbed influence of "nonspecific" molecules produced by other cells either on LPS-derived or concanavalin A (Con A)-activated (5, 6). However, there is no general agreement on the char- blasts. Shortly thereafter, purified blasts were suspended in acteristics or a medium containing 10% fetal calf serum at a concentration of physiologic significance of B-cell growth factor 108/ml and incubated on ice for 1 hr. The blasts were then spun, (BCGF). This is most likely due to the widespread belief that resuspended at the same concentration in the appropriate di- antigens are the BCGF (7). In addition, most assays of B-cell lutions of either supernatant or medium, and kept on ice an- responses do not measure growth directly but measure terminal other hour. All supernatants were then tested in the BCGF differentiation ofputative clonalprogenies to antibody production. assay as described below, in parallel with unadsorbed super- Another variable ofthis situation is the source ofconditioned natants, at appropriate dilutions, and in the convenient media containing competence factors. These are currently pro- mixtures. duced by complex cell mixtures or, in the best approaches, by Gel Filtration. Hybridoma supernatant or Con A-condi- mixtures of cloned T cells with ill-defined populations of "an- tioned media from normal spleen cells were precipitated at 80% tigen-presenting cells. " Furthermore, it is nowwell established saturation with ammonium sulfate on ice for 2 hr. The precip- that a single cell type can produce various mediators with a wide itate was spun down (10,000 rpm; 15 min) and resuspended in range of target cell specificities and biological effects (8). Suc- NaCl/0.01 M Hepes, pH 7.3. Samples (1 ml) were applied to cessful fusions between tumor cells of T origin and activated a ACA 54 column (LKB, Bromma, Sweden) equilibrated with lymphocytes have been described (9), and established hybri- phosphate-buffered 0.3 M NaCl. The column was eluted with doma clones with T helper cell characteristics have been re- the same buffer at 4°C; fractions (2 ml) were collected, sterilized ported (10-12). In view of these observations, it would appear by filtration through 0.45-,um Millipore filters, and assayed for feasible to select for hybrid lines showing only one type of bio- BCGF and TCGF activity at 1:60 to 1:120 dilutions in different logical activity-namely, either growth or maturation of B lym- experiments. phocytes. Assays. The assay for BCGF was carried out on B-cell blasts The publication costs ofthis article were defrayed in part by page charge Abbreviations: BCGF, B-cell growth factor; BCMF, B-cell maturation payment. This article must therefore be hereby marked "advertise- factor; Con A, concanavalin A; LPS, lipopolysaccharide; PFC, plaque- ment" in accordance with 18 U. S. C. §1734 solely to indicate this fact. forming cells; TCGF, T-cell growth factor; TRF, T-cell replacing factor. 7455 Downloaded by guest on September 26, 2021 7456 Immunology: Leanderson et aLPProc. Natl. Acad. Sci. USA 79 (1982) purified by density centrifugation from spleen cell cultures activity for B lymphocytes. The results from the subeloning, on stimulated with LPS (50 Ag/ml; Escherichia coli 055; B5, Difco) the other hand, suggest that, after 6-8 weeks, producing hy- for 20-24 hr as described (6). Blasts were extensively washed brids are relatively stable. As shown below, the hybrid de- and subcultured in microtiter plates at 5 x 104/ml (104 per cul- scribed here has maintained biological activity for >6 months, ture) in the same medium as described above. Hybridoma su- both after freezing and thawing and upon continuous culture. pernatants were titrated into the assay wells, with medium or The BCGF-producing hybridoma (TUH 3) used in these ex- BW 5147-conditioned media as negative controls; restimulation periments expressed both alleles of Thy-i, demonstrating that with LPS provided the positive control. At various periods of it stems from fusion of BW 5147 with a BALB/c T cell. These subculture, the cells were pulsed with [3H]dThd (1 tCi per results also demonstrate that the productions of growth-sup- culture; 1 Ci = 3.7 x 1010 becquerels) for 4 hr, harvested, and porting activities for activated T and B lymphocytes segregate processed for assay of radioactivity. The assay for B-cell matur- in different clones and therefore appear to be distinct molecular ation factor (BCMF) was essentially the same but total IgM-se- entities. creting plaque-forming cells (PFC) were determined in the pro- BCGF: Growth-Promoting Activity for Activated B Cells. tein A plaque assay (16). TCGF assays were performed on T-cell As shown previously (19), activated B cell blasts require the blasts (105/ml), obtained from Con A-stimulated cultures, by continuous presence of a mitotic stimulus for maintenance of titrating the hybridoma supernatants into the assay wells with growth; this stimulus can be provided by nonspecific factors a standard TCGF preparation as positive control (17). Interferon generated by unrelated helper cell activity (5, 6). We have char- assays were performed by titrating the supernatants on a sub- acterized the ability of media conditioned by hybridoma cells clone of mouse L-929 cells with vesicular stomatitis virus as to maintain activated B cell blasts (LPS-derived) in exponential challenge; NIH G 002-902-026 reference preparation was used growth. LPS-activated blasts did not maintain growth when re- as a standard. Assay for TRF activity was carried out by adding .cultured in normal medium, but they did so ifreexposed to LPS the hybridoma supernatant to Mishell-Dutton type cultures or to conditioned medium from TUH 3 hybridoma (Fig. 1). Blast modified to microculture conditions (18) and using anti-Thy-i cell growth often was comparable to that induced by LPS, but and complement-treated spleen cells (106 per culture). it also could be considerably lower. This variation most likely is due to heterogeneity in the LPS blast preparation, and it RESULTS could indicate that not all cycling B cells are reactive to the Cell Fusion and Screening for Factor-Producing Cells. hybridoma-derived activity. Alternatively, the lower response From a fusion between BW 5147 and splenocytes activated for observed with hybridoma supernatants might be due to deple- 18 hr with Con A (5 Ag/ml), 9 growing cultures of 48 seeded tion ofnutrients in the spent medium. We conclude from these were retrieved after the selection procedure. Supernatants from results that TUH 3 cells constitutively produce factors that these nine cultures were tested for different biological activities maintain growth in activated B cells, a biological activity we call (Table 1).
Recommended publications
  • ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are The
    0031-3998/07/6103-0267 PEDIATRIC RESEARCH Vol. 61, No. 3, 2007 Copyright © 2007 International Pediatric Research Foundation, Inc. Printed in U.S.A. ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are the Predominant FGF Ligands Expressed in Human Fetal Growth Plate Cartilage PAVEL KREJCI, DEBORAH KRAKOW, PERTCHOUI B. MEKIKIAN, AND WILLIAM R. WILCOX Medical Genetics Institute [P.K., D.K., P.B.M., W.R.W.], Cedars-Sinai Medical Center, Los Angeles, California 90048; Department of Obstetrics and Gynecology [D.K.] and Department of Pediatrics [W.R.W.], UCLA School of Medicine, Los Angeles, California 90095 ABSTRACT: Fibroblast growth factors (FGF) regulate bone growth, (G380R) or TD (K650E) mutations (4–6). When expressed at but their expression in human cartilage is unclear. Here, we deter- physiologic levels, FGFR3-G380R required, like its wild-type mined the expression of entire FGF family in human fetal growth counterpart, ligand for activation (7). Similarly, in vitro cul- plate cartilage. Using reverse transcriptase PCR, the transcripts for tivated human TD chondrocytes as well as chondrocytes FGF1, 2, 5, 8–14, 16–19, and 21 were found. However, only FGF1, isolated from Fgfr3-K644M mice had an identical time course 2, 17, and 19 were detectable at the protein level. By immunohisto- of Fgfr3 activation compared with wild-type chondrocytes and chemistry, FGF17 and 19 were uniformly expressed within the showed no receptor activation in the absence of ligand (8,9). growth plate. In contrast, FGF1 was found only in proliferating and hypertrophic chondrocytes whereas FGF2 localized predominantly to Despite the importance of the FGF ligand for activation of the resting and proliferating cartilage.
    [Show full text]
  • And Insulin-Like Growth Factor-I (IGF-I) in Regulating Human Erythropoiesis
    Leukemia (1998) 12, 371–381 1998 Stockton Press All rights reserved 0887-6924/98 $12.00 The role of insulin (INS) and insulin-like growth factor-I (IGF-I) in regulating human erythropoiesis. Studies in vitro under serum-free conditions – comparison to other cytokines and growth factors J Ratajczak, Q Zhang, E Pertusini, BS Wojczyk, MA Wasik and MZ Ratajczak Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA The role of insulin (INS), and insulin-like growth factor-I (IGF- has been difficult to assess. The fact that EpO alone fails to I) in the regulation of human erythropoiesis is not completely stimulate BFU-E in serum-free conditions, but does do in understood. To address this issue we employed several comp- lementary strategies including: serum free cloning of CD34؉ serum containing cultures indicates that serum contains some cells, RT-PCR, FACS analysis, and mRNA perturbation with oli- crucial growth factors necessary for the BFU-E development. godeoxynucleotides (ODN). In a serum-free culture model, both In previous studies from our laboratory, we examined the ؉ INS and IGF-I enhanced survival of CD34 cells, but neither of role of IGF-I12 and KL9,11,13 in the regulation of early human these growth factors stimulated their proliferation. The influ- erythropoiesis. Both of these growth factors are considered to ence of INS and IGF-I on erythroid colony development was be crucial for the BFU-E growth.3,6,8,14 Unexpectedly, that dependent on a combination of growth factors used for stimul- + ating BFU-E growth.
    [Show full text]
  • Factor-The Controlling Growth Factor-At a Sufficiently Low Value, While the Cell Population Has Ceased to Grow and Is in a Sort
    708 GENETICS: NO VICK A ND SZILARD PROC. N. A. S. EXPERIMENTS WITH THE CHEMOSTAT ON SPONTANEOUS MUTATIONS OF BACTERIA By AARON NOVICK AND LEO SZILARD INSTITUTRE OF RADIOBIOLOGY AND BIOPHYSICS, UNIVERSITY OF CHICAGO Communicated by H. J. Muller, October 18, 1950 Introduction.-All bacteria require for growth the presence of certain inorganic chemical components in the nutrient, such as potassium, phos- phorus, sulphur, etc., and with a few exceptions all bacteria require an energy-yielding carbon source, such as, for instance, glucose or lactate, etc. In addition to these elements or simple compounds, certain bacteria require more complex compounds, for instance an amino acid, which they are not capable of synthesizing. For the purposes of this presentation, any of the chemical compounds which a given strain of bacteria requires for its growth will be called a "growth factor." In general, the growth rate of a bacterial strain may be within very wide limits independent of the concentration of a given growth factor; but since at zero concentration the growth rate is zero, there must of necessity exist, at sufficiently low concentrations of the growth factor, a region in which the growth rate falls with falling concentration of the growth factor. It therefore should be possible to maintain a bacterial population over an indefinite period of time growing at a rate considerably lower than normal simply by maintaining the concentration of one growth factor-the controlling growth factor-at a sufficiently low value, while the concentrations of all other growth factors may at the same time be main- tained at high values.
    [Show full text]
  • Updated November 2019 KIT Mutation the KIT Gene Is Associated With
    Updated November 2019 KIT Mutation The KIT gene is associated with autosomal dominant piebaldism, gastrointestinal stromal tumors (GISTs), and familial mastocytosis.1-3 The type of mutation identified in the KIT gene determines the symptoms/cancer risks that the individual may have. Pathogenic loss-of-function (LOF) mutations in the KIT gene are generally only associated with Piebaldism. However, pathogenic gain of function mutations in the KIT gene are associated with systemic mastocytosis and gastrointestinal stromal tumors.4,5 Piebaldism: This is a rare condition characterized by the patchy absence of melanocytes in certain areas of the skin and hair. Melanocytes produce the pigment melanin, which contributes to hair, eye, and skin color. The absence of melanocytes leads to patches of skin and hair that are lighter than normal. These unpigmented areas are typically present at birth and do not increase in size or number.6-8 Gastrointestinal stromal tumors (GIST): GISTs are tumors that occur in the gastrointestinal tract, most commonly in the stomach or small intestine. Small tumors may cause no signs or symptoms. However, some people with GISTs may experience pain or swelling in the abdomen, nausea, vomiting, loss of appetite, or weight loss. These tumors can be cancerous (malignant) or noncancerous (benign). Mastocytosis: This is a blood disorder that occurs when white blood cells called mast cells accumulate in one or more tissues (most commonly in the bone marrow). Mast cells normally trigger inflammation during an allergic reaction. When an environmental trigger activates mast cells, they release proteins that signal an immune response. In systemic mastocytosis, excess mast cells mean more proteins are being released in the tissues where the cells accumulate, leading to an increased immune response.
    [Show full text]
  • Human Transforming Growth Factor Α (TGF-Α)
    787 STOMACH Gut: first published as 10.1136/gut.51.6.787 on 1 December 2002. Downloaded from Human transforming growth factor α (TGF-α) is digested to a smaller (1–43), less biologically active, form in acidic gastric juice T Marchbank, R Boulton, H Hansen, R J Playford ............................................................................................................................. Gut 2002;51:787–792 Background: Transforming growth factor α (TGF-α) is a 50 amino acid peptide with potent prolifera- tive and cytoprotective activity present in gastric mucosa and juice. Aims: To determine the forms and biological activity of natural and recombinant TGF-α following incu- bation with acid pepsin. Patients: Human gastric juice was obtained under basal conditions from patients taking acid suppres- sants and from volunteers undergoing intragastric neutralisation. See end of article for Methods: Samples were analysed using mass spectroscopy and/or high pressure liquid chromatogra- authors’ affiliations phy with radioimmunoassay. Biological activity was determined using thymidine incorporation into rat ....................... hepatocytes and an indomethacin/restraint induced gastric damage rat model. α α Correspondence to: Results: TGF- 1–50 is cleaved to TGF- 1–43 by acid pepsin and this is the predominant form in normal Professor R J Playford, gastric juice. However, intragastric neutralisation or taking acid suppressants caused the predominant Gastroenterology Section, α α 3 form to be TGF- 1–50.TGF- 1–43 had only half of the ability to maximally stimulate [ H]thymidine incorpo- Imperial College School of α ration into primary rat hepatocytes (28 177 (1130) DPM/well for 2.16 nM TGF- 1–43 v 63 184 (3536) Medicine, Hammersmith α Hospital Campus, Du Cane DPM/well for TGF- 1–50; p<0.001).
    [Show full text]
  • Insulin As a Growth Factor
    003 1-3998/85/1909-0879$02.00/0 PEDIATRIC RESEARCH Vol. 19, No. 9, 1985 Copyright O 1985 International Pediatric Research Foundation, Inc Printed in U.S. A. Insulin as a Growth Factor D. J. HILL AND R. D. G. MILNER Departrnenl c!j'Pucdiutricc, Unive,:sitj. of Sl~effield,Cliildren :s Hospital, Shefic~ld,England ABSTRACT. Insulin is a potent mitogen for many cell attention than its well known, acute metabolic actions. Insulin types in vitro. During tissue culture, supraphysiological also can influence growth in vivo. The poor growth of a chilld concentrations of insulin are necessary to promote cell with diabetes (1) contrasts with the overgrowth of the hyperin- replication in connective or musculoskeletal tissues. Insulin sulinemic infant of a diabetic mother (2). The growth-promoting promotes the growth of these cells by binding, with low effect of insulin in vivo was demonstrated experimentally by affinity, to the type I insulin-like growth factor (IGF) Salter and Best in 1953 (3); these investigators restored growth receptor, not through the high affinity insulin receptor. In to hypophysectomized rats by treatment with insulin and a high other cell types, such as hepatocytes, embryonal carcinoma carbohydrate diet. Rats given insulin grew as well as those given cells, or mammary tumor cells, the type I IGF receptor is growth hormone but consumed substantially more food. Any virtually absent, and insulin stimulates the growth of these analysis of the action of insulin in promoting growth must clearly cells at physiological concentrations by binding to the high separate those effects which are due to anabolism resulting frc~m affinity insulin receptor.
    [Show full text]
  • Early Decrease in Serum Amphiregulin Or Vascular Endothelial Growth Factor Levels Predicts Sorafenib Efficacy in Hepatocellular Carcinoma
    ONCOLOGY REPORTS 41: 2041-2050, 2019 Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma CORINNE GODIN1,2*, SANDRA BODEAU2,3*, ZUZANA SAIDAK1,4, CHRISTOPHE LOUANDRE2, CATHERINE FRANÇOIS5, JEAN-CLAUDE BARBARE6, ROMAIN CORIAT7,8, ANTOINE GALMICHE1,2 and CHLOÉ SAUZAY1,2 1Equipe CHIMERE, EA 7516, Université de Picardie Jules Verne; 2Laboratoire de Biochimie; 3Laboratoire de Pharmacologie; 4Service d'Oncobiologie Moléculaire, Centre de Biologie Humaine, CHU Sud; 5EA4294, Université de Picardie Jules Verne; 6Délégation à la Recherche Clinique et à l'Innovation, CHU Sud, 80054 Amiens; 7Gastroenterology and Digestive Oncology Unit, Cochin University Hospital, APHP; 8Unité Inserm U1016, Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France Received June 29, 2018; Accepted November 15, 2018 DOI: 10.3892/or.2018.6922 Abstract. Sorafenib is the standard of care for the treatment at the transcriptional and post-transcriptional levels. All HCC of advanced hepatocellular carcinoma (HCC). However, patients in our cohort had detectable concentrations of AREG identifying secreted biomarkers that predict sorafenib efficacy and VEGF both at baseline and after sorafenib treatment. The in all HCC patients remains challenging. It was recently decreased serum levels of AREG and VEGF after 15 days of reported that sorafenib interferes with protein homeostasis sorafenib treatment were significantly associated with better and inhibits global translation in tumour cells. A likely overall and progression-free survival. The results of the consequence of this inhibition would be the interruption multivariate analysis demonstrated that a decrease in AREG of autocrine loops. The aim of the present study was to was an independent prognostic indicator of overall survival investigate the effect of sorafenib on two growth factors (hazard ratio, 0.208; 95% confidence interval, 0.173‑0.673; implicated in autocrine loops and HCC tumour invasion: P=0.0003).
    [Show full text]
  • Natural Human Interleukin-2 (IL-2) / T-Cell Growth Factor (TCGF) Catalog #: 0801017
    Natural Human Interleukin-2 (IL-2) / T-Cell Growth Factor (TCGF) Catalog #: 0801017 PRODUCT CHARACTERISTICS CONTENTS Each lot of IL-2/TCGF is analyzed for its ability to Each 50 ml bottle contains approximately 25,000 stimulate proliferation of seven to ten day old BRMP (Biological Response Modifier Program) PHA-transformed human T- lymphocytes. When units of IL-2/TCGF at a concentration of used at a final concentration of approximately approximately 500 BRMP units/ml. It is supplied 10% (v/v), IL-2/TCGF will induce a minimum five- as a sterile solution in 25mM HEPES buffered fold increase in cell concentration of such cells RPMI 1640 culture medium which is free of when seeded at a density of 2.0 x 105/ ml. IL- serum. IL-2/TCGF protein concentration ranges 2/TCGF, a glycoprotein with a molecular weight from 8-22 µg/ml. of approximately 15,000 kDa, is produced from pooled human PHA-stimulated T-lymphocytes. IL-2/TCGF is purified by several chromatographic STORAGE AND STABILITY steps to remove PHA and interferon. The solution is stable at -10ºC or below. The material may be re-frozen after thawing. RECOMMENDED USAGE Repetitive freezing and thawing is not recommended (aliquot if necessary). Thawed This preparation will support growth of most IL- material may be stored at 4 C for short-term 2/TCGF dependent lymphocyte cultures at a final usage. concentration of 10% (v/v). The initial cell density should be approximately 2.0 x 105/ ml and the cell culture should be adjusted to this density CAUTION: DO NOT USE IN HUMANS.
    [Show full text]
  • Transforming Growth Factor-β in Stem Cells and Tissue Homeostasis
    Bone Research www.nature.com/boneres REVIEW ARTICLE OPEN Transforming growth factor-β in stem cells and tissue homeostasis Xin Xu1, Liwei Zheng2, Quan Yuan3, Gehua Zhen4, Janet L. Crane4,5, Xuedong Zhou1 and Xu Cao4 TGF-β 1–3 are unique multi-functional growth factors that are only expressed in mammals, and mainly secreted and stored as a latent complex in the extracellular matrix (ECM). The biological functions of TGF-β in adults can only be delivered after ligand activation, mostly in response to environmental perturbations. Although involved in multiple biological and pathological processes of the human body, the exact roles of TGF-β in maintaining stem cells and tissue homeostasis have not been well-documented until recent advances, which delineate their functions in a given context. Our recent findings, along with data reported by others, have clearly shown that temporal and spatial activation of TGF-β is involved in the recruitment of stem/progenitor cell participation in tissue regeneration/remodeling process, whereas sustained abnormalities in TGF-β ligand activation, regardless of genetic or environmental origin, will inevitably disrupt the normal physiology and lead to pathobiology of major diseases. Modulation of TGF- β signaling with different approaches has proven effective pre-clinically in the treatment of multiple pathologies such as sclerosis/ fibrosis, tumor metastasis, osteoarthritis, and immune disorders. Thus, further elucidation of the mechanisms by which TGF-β is activated in different tissues/organs and how targeted cells respond in a context-dependent way can likely be translated with clinical benefits in the management of a broad range of diseases with the involvement of TGF-β.
    [Show full text]
  • Erythropoietin and Growth Factors Exhibit Differential Angiogenic Potential in Mouse Heart
    in vivo 22 : 587-592 (2008) Erythropoietin and Growth Factors Exhibit Differential Angiogenic Potential in Mouse Heart OLGA PAGONOPOULOU 1, ANNA EFTHIMIADOU 1, MARIA LAMBROPOULOU 2, NIKOS PAPADOPOULOS 2 and NIKOS K. NIKOLETTOS 1 Departments of 1Physiology and 2Histology – Embryology, Democritus University of Thrace, Medical School, Alexandroupolis, 68100, Greece Abstract. Background: The possible angiogenic effect of functions of EPO, angiogenesis, the process through which recombinant human erythropoietin (rHuEpo) and several new blood vessels arise from preexisting ones, has been possibly angiogenic cytokines such as basic fibroblast growth indicated (5). The potential role of EPO in angiogenesis may factor (bFGF), acidic fibroblast growth factor (aFGF) and be considered as a subset of its possible function in improving vascular endothelial growth factor (VEGF) was investigated overall tissue oxygenation and its antiapoptotic role (5). in mouse heart. Materials and Methods: Mice were divided Recombinant human erythropoietin (rHuEPO) induces a into five groups (n=7/group): A, control; B, rHuEpo-treated; proangiogenic phenotype in human endothelial cells, including C, (aFGF-treated); D, (VEGF-treated); E, (bFGF-treated). both early ( i.e. increase in cell proliferation and matrix The antibody mouse anti-human CD31 was used to evaluate metalloproteinase-2 production) and late (differentiation into the vessels present in histological preparations. Results: The vascular tubes) angiogenic events. In vivo , in the chick embryo results show a significant increase of the vessel number per CAM assay, the angiogenic activity of rHuEPO was similar to optical field in the rHuEpo-treated, the bFGF-treated and that exerted by basic fibroblast growth factor (bFGF), a well- the VEGF-treated animals compared to controls whereas known angiogenic cytokine and endothelial cells of the CAM aFGF did not show a ny significant angiogenic activity.
    [Show full text]
  • Immunocytochemical Study of Transforming Growth Factor Expression in Benign and Malignant Gliomas
    AmericanJournal ofPathology, Vol. 134, No. 4, April 1989 Copyright © American Association ofPathologists Immunocytochemical Study of Transforming Growth Factor Expression in Benign and Malignant Gliomas V. Samuels, J. M. Barrett, S. Bockman, between oncogenes and growth factors has been estab- C. G. Pantazis, and M. B. Allen, Jr. lished for many polypeptide growth factors.4 The autono- From the Departments ofNeurosurgery, Anatomy, and mous production of growth factors has led to the auto- Pathology Medical College ofGeorgia, Augusta, Georgia, crine mechanism for neoplastic conversion. and CoreSCAN, Santa Rosa, California To obtain a more thorough understanding of the ubiq- uitous patterns of polypeptide growth factor production, we performed an immunocytochemical analysis in 20 Immunocytochemical studies usingpolyclonal an- cases of benign and malignant human glial tumors. Glial tibodies to epidermal growth factor (EGF) and tumors were chosen as a model of study because of their transforming growthfactor (TGF) alpha and beta precise morphologic correlation relating to malignant phe- wereperformed on 20 cases ofhuman gliomas. EGF notypes.5 immunoreactive material was detected in both be- nign and malignant glial tumors. In addition, EGF immunoreactive material was detected in normal Materials and Methods brain. TGF-beta was detected in both benign and malignant tumors, but was not detected in normal Twenty human glioma biopsies obtained from archival brain. In contrast, TGF-alpha was highly conserved cases within the Department of Pathology at the Medical in its expression, occurring predominantly in ma- College of Georgia from 1981 to 1984 were examined and lignant compared with benign or normal brain tis- classified by a neuropathologist. Of the 20 specimens, 8 sue (P < 0.0001).
    [Show full text]
  • Loss of Growth Factor Dependence and Conversion of Transforming Growth Factor-/?I Inhibition to Stimulation in Metastatic H-Ras-Transformed Murine Fibroblasts1
    (CANCER RESEARCH 48. 6999-7003. December IS, 1988] Loss of Growth Factor Dependence and Conversion of Transforming Growth Factor-/?i Inhibition to Stimulation in Metastatic H-ras-transformed Murine Fibroblasts1 Lois C. Schwarz, Marie-Claude Gingras,2 Grant Goldberg, Arnold H. Greenberg,3 and Jim A. Wright4 Manitoba institute of Cell Biology, and Departments of Biochemistry [L. C. S., J. A. W.] and Immunology [M. C. G., A. H. G.J, The University of Manitoba, 100 Olivia Street, Winnipeg, Manitoba K3E OV9, Canada ABSTRACT transfected cells are hypersensitive to TGF-0 (12), EGF, and bFGF (13). Furthermore, the effects of TGF-/3 on cells trans Cell lines with varying tumorigenic and metastatic potentials have been fected with the myc-oncogene are dependent on the entire set obtained by transformation of KIT1•¿fibroblastsusing radiation or trans- of GFs present at a given time (14). In contrast, ros-transfected fection with 1-24 H-ras. We have observed an inverse relationship cells can become insensitive to the effects of PDGF, EGF, between metastatic potential and dependence on serum for growth. The TGF-0 (12, 15), and bFGF (13), but are hypersensitive to the effects of basic fibroblast growth factor, platelet-derived growth factor, epidermal growth factor, and transforming growth factor-/?i (TGF-0i) on effects of insulin-like GFs (13). It was postulated that ras- these lines were then examined to determine if the changes in the serum transfected cells secrete their own GFs leading to autocrine dependence of metastatic cells may be due to altered responsiveness to stimulation of growth (16).
    [Show full text]